Vaccine priority groups: interim advice

**JCVI report on priority groups for immunisations during the COVID-19 pandemic**

The committee advises priority vaccination of the following groups:

1. Frontline health and social care workers
2. Those at increased risk of serious disease and death from COVID-19 infection stratified according to age and risk factors

There is ongoing work within the UK to refine the identification of persons at risk of serious disease and mortality from COVID-19 infection. As well as age and underlying co-morbid conditions, the committee notes that early signals have been identified of other potential risk factors, including deprivation and ethnicity. As more evidence on at-risk groups emerges, this work will inform the review of the composition, and order of priority, of groups for vaccination.

A summary for the advice is provided here but please find the full report here at [weblink 1].
Improving access to immunisations for hard to reach 0-19 years population within Berkshire

The National Audit Office (NAO) report ‘Investigation into Pre-School Vaccinations’ (2019) states that ‘Public Health England and NHS England do not use a single consistent national approach to engage with underserved vulnerable communities in improving immunisation uptake. They use an adaptable, locally focused approach and expect regional and local NHS England and Public Health England teams to improve uptake’. In addition, an online survey of over 2000 parents by the Royal Society for Public Health (2019) highlighted that multiple under-served communities do not access vaccination services in traditional ways, for example travellers and recent migrants.

There is a need to provide a service which tailors its approach in targeting these vulnerable communities, such as the Gypsy, Romany, Travellers (GRT) communities, who currently access this service erratically or not at all.

In 2018-19 NHS England failed to meet the Department of Health & Social Care’s performance standard of 95% uptake for pre-school immunisations and in July 2019, PHE projected that circa 90,000 children aged five in England had not received two combined doses of the MMR vaccine. In August 2019, the WHO revealed that it had withdrawn the UK’s measles elimination status. In an attempt to resolve inequalities surrounding hard to reach communities and ensuring access and engagement, Berkshire Healthcare has demonstrated its commitment by establishing an innovative county wide service for the 0-19 years cohort for these vulnerable children and young people who may otherwise remain unreachable and unvaccinated.

Expanding collaborative working relationships have been built upon and considerable networking and promotional work continues to be delivered.

The service involves engaging, educating and empowering families regarding immunisations, raising awareness and promoting children’s immunisations through partnership working via health promotional initiatives pan Berkshire. Advice and support is provided for families and professionals. The service administers immunisations to the age cohort of 5-19 years by undertaking visits to the hard to reach families and in doing so, addresses inequalities of engagement, trust and access. For the age cohort of 0-5 years, the service provides advice and support via phone or face to face and can attend immunisation appointments to provide additional support if required.

A referral system has been established. Geographically, the majority of work is focussed within areas of lower immunisation uptake though large amounts of work continue across Berkshire. Examples of communities benefiting from this service are Gypsy Roma and Traveller (GRT) communities, homeless families, families and children struggling to access surgeries due to complex mental and physical health needs, asylum seekers and refugees, families within refuges, children/young people excluded from school and non-engaging, youth offenders and non-engaging families.
An increase in trust, engagement and immunisation uptake has resulted. Increased awareness of the service has increased contact from families and professionals requesting advice or support. Close integrated working with public health/ public health nursing teams, Children’s Health and Information Services, primary care, schools and expanding working links generally has developed. Improved immunisation education has benefitted communities, families and professionals and, in addition, a greater understanding of family’s views and knowledge regarding vaccines.

Further work includes ongoing networking/ collaborative efforts county wide to improve immunisation awareness, access and uptake, promotional work within and beyond Berkshire. Feedback received from hard to reach families is extremely positive and has improved engagement and uptake. Feedback from health care professionals has evidenced how valuable the service is.

Services trying to engage with these vulnerable communities need to provide considerate and easy access. We should aspire to help vulnerable children in different geographical locations and we must undertake a persistent effort on bridging the gap in all health outcomes which includes immunisations. Immunisations are the cornerstone of public health and immunisations save lives.

If you would like further information, please email nicola.smith@berkshire.nhs.uk.

Call for submissions for our ‘How we did it.’

Calling all practice nurses! We know this year has brought challenges and that many of you have had to rethink and adapt how you deliver the immunisation programmes to parents, families and older adults during the pandemic and we want to offer our thanks and to highlight the role of the PN.

We know that at risk adults and children and adults with a learning disability are vulnerable and want to know how you are working to ensure everyone is up-to-date with their routine vaccinations. You don’t have to be an expert or have experience writing articles just a summary of what you did, what worked well and what you might do differently, who it benefited and how you plan to use those insights to deliver the programme this winter and in the future.

Please email immunisation@phe.gov.uk with ‘How we did it’ submission in the subject line. If you’re not sure, email us and we can help.
HPV for all leaflet translated

As the universal HPV Vaccination programme continues for its second year we are pleased to be able to offer the leaflet ‘HPV for all’ in a range of 15 languages as well as English at weblink 2.

- Arabic
- Bengali
- Czech
- Farsi
- French
- Mandarin
- Pashto
- Polish
- Portuguese
- Punjabi
- Spanish
- Romanian
- Russian
- Tigran
- Urdu

This leaflet provides parents and carers of secondary school students and other eligible young people information on HPV, the vaccination program including how and why it is offered.

Order paper copies in English using product code 1012473A and download translations at weblink 3.

New HPV vaccine coverage data collection tool: 2020 to 2021

As the 2020 to 2021 academic year and the HPV Vaccination programme approaches, the Vaccine Coverage Team at Public Health England has provided an optional school-level vaccine coverage data collection tool to assist with local data collection. The 2020 to 2021 school-based collection tool has been circulated to Local Screening and Immunisation Teams.

The tool can be used to collect school-level data for Year 8 students in the 2020 to 2021 academic year, by gender, and aggregates these data for national reporting to the Local Authority level. The aggregated data can then be copied into the ImmForm 2020 to 2021 annual survey when this becomes available next year. Local Areas that choose to use the tool can estimate real-time coverage throughout the academic year.

The same tool can be used during the following academic year (2021/22) to record HPV vaccination data for when this birth cohort moves into Year 9.

The 2020 to 2021 HPV vaccine coverage tool is available to download at weblink 4 alongside the 2019 to 2020 tool which is still available to download for the Year 9 data. For more information on this tool, please see the User Guide at weblink 4 and guidance videos on how to enter data for the Year 8 cohort and Year 9 cohorts at weblink 5. For further inquiries, please contact adolescent@phe.gov.uk.

A separate tool for collecting MenACWY and Td/IPV school level vaccine coverage data has also been developed for the 2020 to 2021 academic year and is located at weblink 4.
TB, BCG and Your Baby – new poster available to order

Protecting infants against tuberculosis through vaccination is a vital ongoing programme. To increase visibility of this programme we have a new poster for all settings encouraging mothers, particularly those from migrant communities to protect their infants from TB. We also have the corresponding leaflet TB BCG and your Baby available in a range of 10+ languages which we highlighted in vaccine update issue 309 in March.

TB, BCG and your baby leaflet is available to download translated into in Arabic, Bengali, Farsi (Persian), Gujarati, Hindi, Nepalese, Pashto, Punjabi, Somali, Tamil and Urdu. Hard or paper copies of this leaflet in English can also be ordered using the product code: 2900193 at weblink 3.

Rabies and Immunoglobulin Service (RlgS) – no longer a stockholder

The Rabies and Immunoglobulin Service (RlgS) at Colindale is a crossdivisional service supporting the post-exposure treatment of serious infections, through the development of guidance, provision of clinical advice and issuing of immunoglobulins and antitoxins following a detailed risk assessment.

This includes post exposure treatment and clinical management for rabies and botulism (TARGET – Tuberculosis, Acute Respiratory, Gastrointestinal, Emerging/Zoonotic Infections and Travel Health Division), hepatitis A and B (BSHSH – Blood Safety, Hepatitis, Sexually-transmitted Infections and HIV Division) and measles, chickenpox, and diphtheria (Imms – Immunisation and Countermeasures Division). RlgS staff comprise a multi-disciplinary team of nurses, a business manager and administrative support; they are hosted in Immunisation under a consultant virologist. Expert guidance and medical support is provided by consultants from each of the Divisions responsible for their specific topic area. RlgS is a busy service; in the financial year 2019/2020 there were over 4,000 calls; over 3,400 related to rabies prophylaxis or post-exposure treatment, about 250 calls related to hepatitis and over 400 calls relating to varicella zoster or measles.

Immunoglobulins and anti-toxins are rare products that are centrally procured by PHE from a range of manufacturers. Stock is held centrally at Movianto on behalf of PHE, but also at a number of stockholders distributed throughout the country. Stock is no longer held on the Colindale site, and all requests through Colindale will now be delivered by Movianto.

Routine service

RlgS operates between 8am – 5.30pm Monday to Friday. All requests for stock and advice about issuing should be directed to this service (Tel: 0330 1280 1020).

Requests for immunoglobulin/vaccine will generally be ordered by RlgS via ImmForm for delivery to a named responsible clinician to arrive the next working day.
However, there may occasionally be specific urgent situations where product is needed sooner than this, and in these circumstances PHE can issue vaccine/immunoglobulin/anti-toxin through a more rapid delivery.

Alternatively, in some cases vaccine/immunoglobulin/anti-toxin may be able to be collected from the nearest stock holder – Rlgs can provide the contact details. From 1 September 2020 the Colindale site will no longer hold any vaccine, immunoglobulin or anti-toxin.

**Out of hours service**

Outside Rlgs working hours, clinical advice is available through the Colindale Duty Doctor service, between 9am and 5:30pm at weekends and bank holidays. Most issues can wait until the next day, so callers after 5:30pm are encouraged to call back the next morning to speak to Rlgs or the Colindale Duty Doctor service. If immunoglobulin/vaccine/anti-toxin is required out of working hours and cannot wait till the next working day, the product may be able to be collected from a local stock-holder or be issued out of hours for Movianto delivery the next day.

Requests to issue products more urgently will only be considered where there is an immediate threat to life. This would be for botulinum and diphtheria anti-toxin or in the case of rabies post-exposure only for a previously untreated head and neck exposure which is classified as a “RED” using the composite rabies risk. PHE cannot issue products for administration outside of England.

**Ordering and issuing of products**

<table>
<thead>
<tr>
<th>Routine – Delivery and administration required within 24 hours/next working day (For most situations)</th>
<th>Urgent – Delivery and administration required within 6 hours (Only for specific situations where there is an immediate threat to life)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Weekday working hours</strong></td>
<td></td>
</tr>
<tr>
<td>Mon-Fri, 8am to 5.30pm</td>
<td>Contact Rlgs</td>
</tr>
<tr>
<td></td>
<td>Contact Rlgs</td>
</tr>
<tr>
<td><strong>Weekday out of hours</strong></td>
<td></td>
</tr>
<tr>
<td>Mon-Thurs, 5:30pm to 8pm</td>
<td>Contact Rlgs the next morning</td>
</tr>
<tr>
<td></td>
<td>Contact Colindale out of hours duty doctor service</td>
</tr>
<tr>
<td><strong>Weekend out of hours</strong></td>
<td></td>
</tr>
<tr>
<td>Friday from 5.30pm to Saturday 9am</td>
<td>Contact Colindale out of hours duty doctor service the next morning</td>
</tr>
<tr>
<td></td>
<td>Contact Colindale out of hours duty doctor service</td>
</tr>
<tr>
<td>Saturday and Sunday from 9am to 5:30pm</td>
<td>Contact Colindale out of hours duty doctor service</td>
</tr>
<tr>
<td>Saturday 5:30pm to Sunday 9am</td>
<td>Contact Colindale out of hours duty doctor service the next morning (after 9am)</td>
</tr>
<tr>
<td>Sunday 5:30pm to Monday 8am</td>
<td>Contact Rlgs the next morning</td>
</tr>
</tbody>
</table>

Subscribe to Vaccine update [here](#). Order immunisation publications [here](#). For centrally-supplied vaccine enquiries, email: [vaccinesupply@phe.gov.uk](mailto:vaccinesupply@phe.gov.uk)
Shingles vaccination programme

Individuals become eligible for routine vaccination against shingles when they become 70 years of age and for those in the catch-up cohort, if they are 78 or 79 years of age. All eligible individuals retain eligibility to receive the shingles vaccine until they become 80 years of age. As lockdown and shielding measures are easing, this a reminder that the shingles vaccine can be offered opportunistically to the cohorts outlined above. Shingles vaccination as part of the routine immunisation programme is covered under the national PHE PGD and may be administered at the same time as the pneumococcal vaccine (Pneumovax 23) and when available, inactivated influenza vaccines.

Some individuals who were eligible for the Shingles (catch-up) vaccination programme may have turned 80 years during the COVID-19 pandemic and missed the opportunity to be vaccinated, either due to lockdown or because they were shielding at home and unable to attend their general practice. This cohort of individuals is likely to be very small and can still be offered shingles vaccine unless contraindicated, up to the 31 December 2020.

This temporary offer applies only to those who missed shingles vaccination because they were shielding and who turned 80 years of age during that period. It is only applicable to periods of time when lockdown or shielding was recommended. Payment for this should be at the same rate as other shingles vaccines and will be managed by local commissioners.

As this cohort will not be included in the Shingles PGD, a Patient Specific Direction (PSD) should be used by practices for this specific cohort of patients. Visit [weblink 3](#) to see the Shingles leaflets, posters, postcards available to order now.

Updated Patient Group Directions (PGDs) are now published

**Inactivated Influenza PGD v08.00 (Gateway number: GW-1533).**
This is to replace the Inactivated Influenza PGD V07.00 (GW-497) and is valid from 1 September 2020.

**LAIV PGD v09.00 (Gateway number: GW-1458).**
This is to replace the LAIV PGD V08.00 (GW-498) and is valid from 1 September 2020.

**PPV PGD v03.00 (Gateway number: GW-1457).**
This is to replace the PPV PGD V02.00 (Gateway number: 2016262) and is valid from 1 September 2020.

These attached PGDs have now been published on the PHE webpages and are available at [weblink 7](#).

**BCG Vaccine AJV PGD v02.00 (Gateway number: GW-1459).**
This is to replace the BCG Vaccine AJV PGD V01.00 (Gateway number: 2018396) and is valid from 1 September 2020.
Training and guidance

Guidance on immunisation training for the 2020/21 flu season

With the ongoing global COVID-19 pandemic, it is more important than ever that this year’s annual flu vaccination programme is safely and effectively delivered to as many of those eligible as possible in order to protect those at risk. It is therefore crucial that those giving flu vaccine are confident, competent and have up to date knowledge about the vaccine(s) they are giving. To support healthcare professionals delivering the flu vaccine programme in the 2020 to 2021 flu season, PHE have published guidance on flu immunisation training. This describes what flu immunisers need to know and various ways in which they can obtain training. There is also a flu-specific competency assessment tool for those new to giving flu vaccines this year. Please see weblink 8.

Flu Immunisation e-learning programme updated

The Flu Immunisation e-learning programme written by PHE and produced by Health Education England e-Learning for Healthcare (HEE e-LfH) has been updated for the 2020 to 2021 flu season.

The programme consists of three knowledge sessions and three assessment sessions. All those undertaking this e-learning should complete the Core Knowledge session and accompanying assessment as this is designed to provide essential knowledge about what flu is and the rationale for, and design of, the annual flu programme. Depending on which session(s) is relevant to your role, you can then complete one or both of the subsequent knowledge and assessment sessions which provide more detailed information about the live and inactivated flu vaccines.

This elearning programme is free and open access for all. For more information about the programme, see: weblink 9.

Immunisation services and large-scale vaccination delivery during COVID-19

The RCN guidance: Immunisation services and Large-scale vaccination delivery during COVID-19 – considerations and practical advice, resource at weblink 10. It is currently written for the influenza programme as a web resource.
Time to apply for a PhD?
There are three 3-year full-time PhD studentships with HPRU in Immunisation to start in January or April 2021. The application deadline is the end of the month (31 August 2020).

The 3 opportunities are listed on the LSHTM studentship pages here:
- 2020 to 2021 NIHR HPRU Vaccines & Immunisation Theme 1 PhD Studentships at [weblink 11](#)
- NIHR HPRU Immunisation Doctoral Studentship at [weblink 12](#)
- Also listed on the HPRU website at [weblink 13](#)

31st National Immunisation Conference for Healthcare Workers
Friday 4 December 2020, 8.00 – 5.30pm (via Zoom)
The 31st meeting of the National Immunisation Conference for Healthcare Workers will take place on 4 December 2020 between 8.00am – 5.30pm.

This edition of the conference will be a virtual, an online Zoom-based event.

We would like to invite entries for the poster competition on any relevant topic for immunisation. We are requesting all entries to supply a poster and a short (5 minutes maximum) podcast about the poster, and we will use these to shortlist the best five to be presented over Zoom in the main room at the end of the conference.

All posters should be in LANDSCAPE (horizontal) format and saved as a PDF, PPTX, PPT, JPEG or PNG file. There are no required dimensions or size limit due to the virtual nature of the poster (but are easier to email if <20MB). Users will be able to download the poster and zoom in/out for optimal viewing.

The format of the podcast should be a Zoom recording (please see the attached guidance on how to create your own Zoom podcast).

The posters and podcasts will be available in a breakout room over Zoom from Monday 30 November – Thursday 3 December for delegates to review – we will take your submission of a poster as an indication that you agree with this – further details will follow of how to access this aspect of the poster programme.

If you would like help developing or creating your poster – please contact Martin Guppy at guppy@btinternet.com who provides medical writing and scientific design services.

The closing date for submissions to Professor Ray Borrow is Friday 30 October. Further details can be obtained from ray.borrow@phe.gov.uk.
PNEUMOVAX® 23 (pneumococcal polysaccharide vaccine) pre-filled syringe presentation

The presentation of the pneumococcal polysaccharide vaccine (PPV) has been switched to a pre-filled syringe presentation called PNEUMOVAX® 23 and vials have now been discontinued. PNEUMOVAX® 23 pre-filled syringe is fully reimbursed for use under the national immunisation programme.

A combination of growing global demand for PPV, alongside manufacturing constraints, have led to regular interruptions in supply of PPV to the UK since 2017. The introduction of a pre-filled syringe presentation of PPV is intended to support the continuity of supply and to help address public health need.

Practices should ensure they are ordering PNEUMOVAX® 23 pre-filled syringes through AAH online at weblink 14. Customers will need an AAH account to place an order. For more information about the vaccine, please refer to the Summary of Product Characteristics.

Coming up: teleconference on flu vaccination

Next month PHE will publish a new edition of Health Matters on flu vaccination. Created as a resource for public health professionals, NHS colleagues and frontline health and social care workers, this edition will focus on all aspects of delivery of the 2020 to 2021 flu immunisation programme, including the challenges presented by COVID-19. A teleconference with PHE policy experts will be held to launch the publication. For further details about this event, either:

Click here to register for the teleconference on 29 Sep 2020

or sign-up to the Health Matters bulletin for more information

Vaccine supply
Routine vaccination programme

Vaccines for the 2020 to 2021 children’s flu programme supplied by PHE: Vaccine availability

Fluenz® Tetra (LAIV) and an egg-based inactivated vaccine (QIVe) will be available to providers of the children’s flu programme in England via PHE’s ImmForm website. Ordering for these vaccines will commence on the dates shown in the table below. Please note that as always, these timings are subject to change. The most up to date information on timing of availability can be found on the news item of the ImmForm website.
First deliveries for Fluenz® Tetra will be made from Wednesday 2 September.

PHE does not supply any flu vaccines for patients aged 18 years and over. Please refer to guidance from your respective health departments for arrangements in Scotland, Wales and Northern Ireland.

Editing Fluenz® Tetra orders
Due to the anticipated large volume of orders for Fluenz® Tetra in the first few weeks of ordering, orders for this product will be assembled as soon as they are placed and will not be editable. If you need to make an adjustment to your order after it has been placed, please contact helpdesk@immform.org.uk.

Vaccine ordering information for General Practice
Ordering controls will be in place for Fluenz® Tetra to enable PHE to balance incoming supply with demand. As in previous years ordering controls for general practices are tailored to each practice and allocate an amount of vaccine based on the number of registered eligible patients.

Increases to the allocations will be applied as soon a sufficient stock becomes available to do so. Exact timings have not yet been defined, however we expect to be able to facilitate the following:

- each GP practice will initially be allocated sufficient vaccine to vaccinate at least 50% of their eligible children (all 2 and 3 year olds, plus children in clinical risk groups from age 4 to <18 years) when ordering commences
- subsequently, each GP practice will be allocated sufficient vaccine to vaccinate at least 70% of their eligible cohort (as above) by early October
- further amendments to increase these allocations will be made in response to demand and vaccine availability
- requests for extra vaccine will be considered on a case by case basis throughout

At the time of publication this schedule remains subject to change. Any changes will be communicated via the news item on the ImmForm front page.

Requests for additional vaccine should be sent to the ImmForm helpdesk (helpdesk@immform.org.uk/0207 183 8580) and should be sent in good time before your order cut-off. Out of schedule deliveries will be by exception only.
Multi-branch practices and Fluenz® Tetra allocations

Please note that GP practices or groups that operate over multiple sites but are part of the same organisation will have a joint allocation (as in previous years), even where each site has a unique ImmForm account.

This means that it is possible for one site to potentially order all of the available vaccine for the group, unless there is local agreement on how the allocated volume is shared across multi-branch practices. PHE recommend that this agreement is in place before ordering opens to reduce the risk of supply interruption. The information above allows practices to estimate the amount of vaccine they will be allocated and how it should be split between all sites.

Vaccine ordering information for school-age providers

A default ordering cap of 300 packs (3,000 doses) per week, per ImmForm account will be in place for school providers. Where this cap is insufficient and a provider needs a larger weekly volume of vaccine to deliver the programme (for example where a provider covers a large area using a single account), a higher weekly cap should be requested via the PHE Vaccine Operations team by emailing vaccinesupply@phe.gov.uk.

Requests should be made by Friday 21 August to ensure that accounts are set up correctly before vaccine ordering commences. For one-off larger orders, requests should be made via helpdesk@immform.org.uk in good time before the order cut-off.

Inactivated flu vaccine ordering for children in clinical risk groups, for whom LAIV is unsuitable

PHE also supplies an egg-based Quadrivalent Influenza Vaccine (split virion, inactivated) which is suitable for all children from six months to less than 18 years old. This vaccine will have an initial order cap of 20 doses per week.

Full details of the vaccine arrangements for children in clinical risk groups aged 9 years and over who are contraindicated for Fluenz® Tetra can be found in the flu letter published Thursday 14 May 2020 (weblink 14). PHE does not supply any flu vaccines for patients aged 18 years and over.

Supply of inactivated flu vaccine for children who object to LAIV due to the porcine gelatine content.

A supply of inactivated influenza vaccine is expected to be made available to NHS providers of the children’s flu programme, for children who object to the porcine gelatine content of Fluenz® Tetra (LAIV) from November. Arrangements for this supply have not yet been finalised and further details will be communicated as soon as they are available. Until then, the limited supply of Quadrivalent Influenza Vaccine (split virion, inactivated) that is available to order through ImmForm must be prioritised for children in clinical risk groups aged 6 months to less than 9 years.

All influenza vaccines for the 2020 to 2021 season

Information on all influenza vaccines that have been marketed in the UK for the 2020 to 2021 season are available at weblink 15.
Maternal Pertussis programme – Change to dTaP/IPV vaccine

This is a reminder that Repevax® vaccine (dTaP/IPV) continues to be the vaccine to order for use in the maternal pertussis immunisation programme. The maternal pertussis immunisation programme commenced in October 2012, initially using Repevax® vaccine (dTaP/IPV). From July 2014, Boostrix®-IPV (dTaP/IPV) has been supplied. Repevax® is now available to order through ImmForm for use in the maternal pertussis immunisation programme instead of Boostrix®-IPV.

This is a temporary change and it is anticipated that supplies will revert to Boostrix®-IPV in autumn 2020. This change is necessary as PHE is running down all stock of Repevax® before the introduction of Boostrix®-IPV across both the maternal pertussis and the pre-school booster programmes. There is no other change to the maternal pertussis immunisation programme, further details about this programme can be found in chapter 24 of the Green Book at weblink 6.

Update to Bexsero Patient Information Leaflet

Every pack of Bexsero (Meningitis B vaccine; 10 doses) is supplied with a pad of ten Patient Information Leaflets (PILs), as well as there being a single PIL inside each Bexsero pack. Since late-September 2019, an updated version of the PIL pad has been distributed with Bexsero orders. Please dispose of the single PIL from inside the pack, as it will be out-of-date. We will advise further when the PIL supplied in the pack is in line with the PIL pad.

MMR vaccine ordering

There are currently two different vaccines available to order for the MMR programme, MMRvaxPRO® and Priorix®. Orders for Priorix® are capped at 10 packs per order per week for accounts in England and Wales. Controls are also in place for Scottish customers. This is needed to rebalance central supplies.

The alternative MMR vaccine, MMRvaxPRO®, remains available to order without restriction. If you specifically require additional Priorix® stock, for example because you serve communities that do not accept vaccines that contain porcine gelatine then please contact the ImmForm Helpdesk for assistance at helpdesk@immform.org.uk or 0207 183 8580.

The EU Falsified Medicines Directive (FMD) and Delegated Regulation as applicable to PHE supplied vaccines for the national immunisation programme

Full information on FMD as it applies to centrally supplied vaccines for the National Immunisation Programme can be found in the April 2019 edition of Vaccine update at weblink 16.

ImmForm vaccines in FMD-compliant packs (i.e. subject to the requirements of the Delegated Regulation) are being distributed for all centrally supplied products. We would encourage all of our customers to visit the GOV.UK page on FMD at weblink 17 and spend some time becoming familiar with the content and links to various other guidance documents on the implementation of the legislation.
If you have identified yourself to PHE as being exempt from decommissioning under Article 23 of the Delegated Regulation and this has been agreed, then you will be supplied with decommissioned vaccine.

Please see our guidance for more information on the roles and responsibilities in relation to FMD and the Delegated Regulation, regarding vaccines and other medicines centrally supplied by PHE to the NHS and other customers. This document is accessible via GOV.UK at weblink 18.

Please note that the barcode on Rotarix batch AROLC284AA (exp. 31/05/2021) is non-serialised and therefore cannot be verified or decommissioned; however, it can still be used.

Summer bank holiday delivery and order cut-off changes

Due to the August Bank Holiday, there will be no deliveries or order processing by Movianto UK on Monday 31 August 2020. Please see the table below for revised order and delivery dates. For customers with standard delivery dates of Monday please be aware that after the 24 of August 2020, your next available delivery day will be the 7 September 2020.

Customers are reminded to be prepared for the break in deliveries and to order accordingly. Please make sure you have sufficient room in your fridge for any additional vaccine you wish to stock over this holiday period, bearing in mind the recommendation that only two to four weeks of vaccine stock be held at any one time. Out of Schedule deliveries cannot be arranged for failure to place orders in good time.

<table>
<thead>
<tr>
<th>August Bank Holiday – Monday 31 August 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Delivery date</strong></td>
</tr>
<tr>
<td>Monday 24 August 2020</td>
</tr>
<tr>
<td>Tuesday 25 August 2020</td>
</tr>
<tr>
<td>Wednesday 26 August 2020</td>
</tr>
<tr>
<td>Thursday 27 August 2020</td>
</tr>
<tr>
<td>Friday 28 August 2020</td>
</tr>
<tr>
<td>Monday 31 August 2020</td>
</tr>
<tr>
<td>Tuesday 1 September 2020</td>
</tr>
<tr>
<td>Wednesday 2 September 2020</td>
</tr>
<tr>
<td>Thursday 3 September 2020</td>
</tr>
<tr>
<td>Friday 4 September 2020</td>
</tr>
</tbody>
</table>
ImmForm web address has changed

As part of planned works to ensure continued availability of the ImmForm website, the web address has changed to https://portal.immform.phe.gov.uk. There is currently an auto-redirect from the old address to the new web address. However, please update your shortcut or favourite links to the new PHE URL before November 2020.

For assistance please contact the ImmForm Helpdesk by calling 0207 183 8580 or emailing helpdesk@immform.org.uk.

Registering for a new or updating your existing ImmForm vaccine ordering account:

When you register for or update an existing ImmForm account, Public Health England as a wholesaler of vaccines need to verify the requesting customer.

Please ensure you have your professional regulatory body registration number or Wholesaler Dealer Licence and an organisation code which can be verified when requesting updates or requesting a new vaccine ordering account.

For more information please see the ImmForm Helpsheet – How to register at weblink 19.

Vaccine supply

Non-routine vaccination programme

HEPATITIS A VACCINE

Adult
- **GSK**: Havrix Adult PFS singles and packs of 10 are available
- **Sanofi Pasteur**: Avaxim PFS singles and packs of 10 are available
- **MSD**: VAQTA Adult is available

Paediatric
- **GSK**: Havrix Paediatric PFS singles and packs of 10 are available
- **MSD**: VAQTA Paediatric is available

HEPATITIS B VACCINE

Adult
- **GSK**: Engerix B PFS singles and packs of 10 are available
- **GSK**: Limited supplies of Engerix B single vials remain available within the wholesaler network
- **GSK**: Engerix B vials packs of 10 are unavailable
- **GSK**: Fendrix is available
- **MSD**: HBVAXPRO 10 µg is unavailable until further notice
- **MSD**: HBVAXPRO 40 µg is unavailable until further notice

Paediatric
- **GSK**: Engerix B Paediatric singles are available
- **MSD**: HBVAXPRO 5µg are available
COMBINED HEPATITIS A & B VACCINE
- **GSK**: Twinrix Adult singles and packs of 10 are available
- **GSK**: Twinrix Paediatric is available
- **GSK**: Ambirix is available

COMBINED HEPATITIS A & TYPHOID VACCINE
- **Sanofi Pasteur**: Viatim is available

TYPHOID VACCINE
- **Sanofi Pasteur**: Typhim singles and packs of 10 are available
- **Emergent**: Vivotif is available

RABIES VACCINE
- **GSK**: Rabipur is currently available
- **Sanofi Pasteur**: Rabies BP is currently out of stock. An alternative vaccine is available, please contact Sanofi Pasteur directly for more information

PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV)
- **MSD**: Pneumococcal Polysaccharide Vaccine vials are now unavailable. There has been a switch from the vials to the Pneumovax 23 prefilled syringes (PFS). Limited supplies of the Pneumovax PFS are available. (Please see page 12 of the Bug Special Vaccine Update issue 300, October 2019 for further information)
- **MSD**: Limited supplies of PNEUMOVAX 23 PFS are currently available

PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (PCV)
- **Pfizer**: Prevenar 13 is currently available

VARICELLA ZOSTER VACCINE
- **GSK**: VARILRIX is currently available
- **MSD**: VARIVAX is currently available
- **MSD**: ZOSTAVAX is available

DIPHTHERIA, TETANUS AND POLIOMYELITIS (inactivated) VACCINE
- **Sanofi Pasteur**: Revaxis is available

DIPHTHERIA, TETANUS, PERTUSSIS (acellular) AND POLIOMYELITIS (inactivated) VACCINE
- **GSK**: Supply of Boostrix-IPV is currently available

MMR
- **MSD**: MMRvaxPro is currently available
- **GSK**: Priorix is currently available.
MENINGITIS ACWY VACCINE
• GSK: Menveo is available
• Pfizer: Nimenrix is currently available

YELLOW FEVER
• Sanofi Pasteur: Stamaril is available

HUMAN PAPILLOMAVIRUS VACCINE
• MSD: Limited supply of GARDASIL is available. Supplies for the national immunisation programme are unaffected
• MSD: Gardasil 9 is currently available
• GSK: Cervarix is currently available

CHOLERA VACCINE
• Valneva: Dukoral is available

JAPANESE ENCEPHALYTIS VACCINE
• Valneva: Ixiaro is available

Coming soon
Winter! Vaccine update Flu special
Weblinks

Weblink 2  www.gov.uk/government/publications/hpv-vaccine-vaccination-guide-leaflet
Weblink 3  www.healthpublications.gov.uk/Home.html
Weblink 5  https://publichealthengland-immunisati.app.box.com/s/n2oqm0fize4zpi9r10aoayes6dv6llzp
Weblink 7  www.gov.uk/government/collections/immunisation-patient-group-direction-pgd
Weblink 8  www.gov.uk/government/publications/flu-immunisation-training-recommendations
Weblink 9  www.e-lfh.org.uk/programmes/flu-immunisation
Weblink 11 www.lshtm.ac.uk/study/fees-and-funding/funding-scholarships/2020-21-nihr-hpru-vaccines-immunisation-theme-1-phd-studentships
Weblink 12 www.lshtm.ac.uk/study/fees-and-funding/funding-scholarships/2020-21-nihr-hpru-immunisation-doctoral-studentship